# US 2015/0175973 A1 · Highly efficient method for establishing induced pluripotent stem cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175973 A1
- Document ID: US20150175973A1
- Status: Published application
- Kind: A1
- Application number: 14/402,310
- Filed: 2013-05-23
- Published: 2015-06-25
- Earliest claimed: 2012-05-23
- Assignees: Kyoto University
- Applicants: Kyoto University
- Inventors: Shinya Yamanaka; Keisuke Okita
- Web page: https://patentgrep.com/patent/US20150175973A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C07K 14/005: from viruses
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2501/60: Transcription factors
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2501/608: Lin28
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/11: from blood or immune system cells
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N 2710/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a production method of iPS cell, including a step of introducing the following (1) and (2): (1) an episomal vector containing a nuclear reprogramming factor; and (2) an episomal vector containing EBNA-1, which is different from (1), into a somatic cell, as well as a method for improving iPS cell establishment efficiency. The present invention also provides an agent for improving iPS cell establishment efficiency, which contains an episomal vector containing a nucleic acid encoding EBNA-1, and a kit for producing an iPS cell further containing an episomal vector containing a nucleic acid encoding a nuclear reprogramming factor.

## Claims

### Claim 1

A method of producing an iPS cell, comprising a step of introducing the following (1) and (2):
(1) one or more episomal vectors containing a nucleic acid encoding a nuclear reprogramming factor; and
(2) an episomal vector containing a nucleic acid encoding EBNA-1, which is different from (1)
into a somatic cell.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising introducing a nucleic acid, encoding an inhibitor of p53 function, in the form of an episomal vector.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the inhibitor of p53 function is p53 shRNA or a dominant negative mutant of p53.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the dominant negative mutant of p53 is p53DD.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the nuclear reprogramming factor is one or more selected from the group consisting of the members of Oct family, Klf family, Sox family, Myc family, Lin family and Glis family.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the nuclear reprogramming factors are Oct3/4, Klf4, Sox2, L-Myc and Lin28.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the nuclear reprogramming factors are Oct3/4, Klf4, Sox2, L-Myc, Lin28 and Glis1.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the nucleic acid encoding a nuclear reprogramming factor is divided and contained in 2 or 3 episomal vectors.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the episomal vectors containing the nucleic acid encoding a nuclear reprogramming factor are pCEB-hSK-O and pCEB-hUL-G.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the episomal vectors containing the nucleic acid encoding a nuclear reprogramming factor are pCXLE-hOCT3/4, pCXLE-hSK and pCXLE-hUL.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the episomal vectors containing the nucleic acid encoding a nuclear reprogramming factor are pCXLE-hOCT3/4-shp53-F, pCXLE-hSK and pCXLE-hUL.

### Claim 12 (depends on 2)

The method according to claim 2, wherein the episomal vectors containing the nucleic acid encoding a nuclear reprogramming factor are pCE-hOCT3/4-shp53, pCE-hSK and pCE-hUL.

### Claim 13 (depends on 2)

The method according to claim 2, wherein the episomal plasmid vectors containing the nucleic acid encoding a nuclear reprogramming factor are pCE-hOCT3/4, pCE-hSK and pCE-hUL, and the episomal vector containing the nucleic acid encoding an inhibitor of p53 function is pCE-mp53DD.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the plasmid vector containing the nucleic acid encoding EBNA-1 is pCXWB-EBNA1.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the plasmid vector containing the nucleic acid encoding EBNA-1 is pCXB-EBNA1.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the somatic cell is selected from human fibroblast (HDF) and blood cell.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the blood cell is a peripheral blood mononuclear cell (PMNC).

### Claim 18 (depends on 17)

The method according to claim 17, wherein the peripheral blood mononuclear cell (PMNC) is a T cell.

### Claim at position 19

-35. (canceled)
